Among the major areas of care fixated by people is their health. As such, advances in medicines are duly welcome and highly appreciated. Progress in research of various diseases and development of drugs to help curb them is always a good indicator. One such aspect of progress has been noted in liposomal formulation.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
Liposomes bio structure is favorable. They are mainly aqueous at the core. This is close in by a layer of phospholipids. Various strains have different types of phospholipids they could be either natural or synthetically prepared in a laboratory. This provides an ideal state where both extremes of drugs can be safely transported, by either attaching to the liquid core or the lipid outer layers.
Researchers have found the process of formation of these compounds may be critical to their performance. They are formed when strands of phospholipids are put in water, and a given heat amount is directed to them. The composition of the formed liposomes is tested against that of this drug it is intended to carry, so as to determine compatibility and avoid destructive reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
Liposomes bio structure is favorable. They are mainly aqueous at the core. This is close in by a layer of phospholipids. Various strains have different types of phospholipids they could be either natural or synthetically prepared in a laboratory. This provides an ideal state where both extremes of drugs can be safely transported, by either attaching to the liquid core or the lipid outer layers.
Researchers have found the process of formation of these compounds may be critical to their performance. They are formed when strands of phospholipids are put in water, and a given heat amount is directed to them. The composition of the formed liposomes is tested against that of this drug it is intended to carry, so as to determine compatibility and avoid destructive reactions.
When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
About the Author:
Discover the concept of liposomal formulation by reading our published blogs. To know more about the topic, visit the relevant website right now at http://purensm.com.
No comments:
Post a Comment